RASAZILECT rasagiline mesilate 1 mg tablets, blister

Država: Australija

Jezik: engleski

Izvor: Department of Health (Therapeutic Goods Administration)

Aktivni sastojci:

rasagiline mesilate, Quantity: 1.56 mg

Dostupno od:

Arrotex Pharmaceuticals Pty Ltd

Farmaceutski oblik:

Tablet, uncoated

Sastav:

Excipient Ingredients: purified talc; microcrystalline cellulose; maize starch; citric acid; silicon dioxide; pregelatinised maize starch; stearic acid

Administracija rute:

Oral

Jedinice u paketu:

10, 30

Tip recepta:

(S4) Prescription Only Medicine

Terapijske indikacije:

Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).

Proizvod sažetak:

Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Status autorizacije:

Registered

Datum autorizacije:

2018-01-23